Telix Adds Ex-Pfizer CMO and Stryker CFO to Board as It Scales Globally

Telix bolsters governance with two heavyweight board appointments

Telix Pharmaceuticals Limited (ASX: TLX) has appointed two Non-Executive Directors to its board, effective 11 May 2026, as part of a strategic governance upgrade. The dual-listed radiopharmaceutical company welcomes Dr. Maria Rivas and Mr. William (Bill) Jellison, both bringing S&P 100 and major U.S. public company experience to the table.

The Telix board director appointments follow the recent addition of David Gill, signalling a broader push to strengthen governance capabilities as the company scales its commercial operations globally. Both appointees bring deep expertise in U.S. corporate governance, financial oversight, and clinical development, directly supporting Telix’s evolution as a dual-listed entity on both the ASX and NASDAQ.

Strong board composition attracts institutional investment and improves corporate governance ratings, whilst diverse expertise helps management navigate complex regulatory and commercial environments. For shareholders, this represents a proactive move to align board capabilities with the company’s maturation as a global, commercial-stage biopharmaceutical business.

Who is Dr. Maria Rivas?

Dr. Maria Rivas is a clinical development and commercialisation leader with more than 25 years of pharmaceutical experience. Most recently serving as Chief Medical Officer at Pfizer Inc. (NYSE: PFE), Dr. Rivas brings deep oncology and rare disease expertise to Telix’s board. Her track record includes overseeing the launch of multiple blockbuster medical products and managing global operations of several thousand data scientists, healthcare experts, and field staff.

Dr. Rivas’s key credentials:

• Former Chief Medical Officer at Pfizer (NYSE: PFE), an S&P 100 company
• Current board position at The Cooper Companies, Inc. (NASDAQ: COO), a medical technology company
• Former independent director at Medidata (NASDAQ: MDSO) from 2018-2019 until its successful merger with Dassault Systèmes
• Education: B.A. in Biochemistry (Brandeis University), MD (Columbia University’s Vagelos College of Physicians and Surgeons)
• Medical training: Residency in Internal Medicine and fellowship in Endocrinology at New York-Presbyterian Hospital

Dr. Rivas has developed and commercialised medical devices and pharmaceutical products across multiple therapeutic areas, including oncology, rare diseases, and neurosciences. This experience is directly relevant to Telix’s radiopharmaceutical pipeline, particularly as the company advances late-stage programmes requiring regulatory and commercial expertise.

Her appointment strengthens the board’s clinical development oversight, a critical capability for a company navigating complex approval pathways and market access challenges in oncology therapeutics.

Who is William (Bill) Jellison?

Mr. William (Bill) Jellison is a corporate finance and audit committee leader with over 30 years of experience in large, regulated operating environments. Most recently serving as Vice President and Chief Financial Officer at Stryker Corporation (NYSE: SYK), Mr. Jellison brings expertise in SEC reporting, mergers and acquisitions, and capital allocation to Telix’s board.

Mr. Jellison’s key credentials:

• Former Vice President and CFO at Stryker Corporation (NYSE: SYK)
• Current board positions at Medtronic plc (NYSE: MDT), Anika Therapeutics, Inc. (NASDAQ: ANIK), Avient Corporation (NYSE: AVNT), Solenis LLC, and Young Innovations, Inc.
• Recent board position at Masimo Corporation (NASDAQ: MASI)
• Education: B.A. in Business Administration (Hope College)

During his executive career, Mr. Jellison oversaw international finance, SEC reporting, mergers and acquisitions, and capital allocation at Stryker. This financial oversight expertise is critical for a company scaling commercial operations globally, particularly one managing dual-listing compliance requirements across the ASX and NASDAQ.

Mr. Jellison’s M&A experience is particularly valuable as Telix pursues growth opportunities in the radiopharmaceutical sector. His audit committee leadership across multiple public companies brings rigorous financial governance capabilities to the board.

What does board composition mean for investors?

Non-Executive Directors play a crucial governance role by providing independent oversight of management decisions, strategic direction, and shareholder interests. Unlike executive directors who run day-to-day operations, NEDs bring external expertise, challenge management assumptions, and ensure the company operates in shareholders’ best interests.

Experienced directors contribute networks, credibility, and operational insights without being involved in daily management. They sit on key committees (audit, remuneration, risk), scrutinise financial reporting, and help navigate complex regulatory environments.

For Telix shareholders, the addition of directors with S&P 100 and major public company experience elevates the board’s collective capability. Strong boards attract institutional investment, improve governance ratings, and provide strategic oversight that supports long-term value creation.

Strategic context and Telix’s evolution

Telix Interim Chair, Dr. Mark Nelson, framed the appointments within the company’s broader governance upgrade and dual-listing strategy:

Dr. Mark Nelson, Interim Chair

“We are delighted to welcome Maria and Bill, highly accomplished Non-Executive Directors whose collective experience in U.S. public company governance, financial oversight and clinical leadership will significantly enhance the Board’s capability. Along with the recent addition of David Gill, these appointments are well aligned with Telix’s evolution as a dual-listed, global, commercial stage biopharmaceutical company.”

The appointments form part of board expansion and succession planning announced 9 April 2026, with both directors commencing 11 May 2026 (subject to grant of Australian Director Identification numbers). The timing aligns with Telix’s transition from a development-stage biotechnology company to a commercial-stage entity with approved products and global operations.

As a dual-listed company on both the ASX and NASDAQ, Telix faces heightened governance and disclosure obligations. The addition of directors with deep U.S. public company experience strengthens the board’s ability to navigate SEC reporting requirements, NASDAQ listing rules, and cross-border regulatory complexity.

The governance upgrades demonstrate the board’s proactive approach to supporting Telix’s growth trajectory, signalling confidence in the company’s strategic direction and commercial momentum.

Key takeaways for Telix shareholders

1. Two experienced U.S. public company directors appointed effective 11 May 2026, bringing S&P 100 and major public company governance experience to Telix’s board.

2. Combined expertise spans clinical development, commercialisation, financial oversight, and M&A, directly supporting Telix’s evolution as a global, commercial-stage radiopharmaceutical company.

3. Appointments align with Telix’s maturation as a dual-listed entity, strengthening board capabilities in U.S. corporate governance, SEC reporting, and strategic oversight as the company scales commercial operations globally.

Want the Next Healthcare Breakthrough in Your Inbox?

Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get market-moving announcements delivered straight to your inbox the moment they drop.